Two Sigma Investments
KALV

Two Sigma Investments’s KalVista Pharmaceuticals KALV Stock Holding History

Two Sigma Investments’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.09M Buy
+153,459
New +$2.47M ﹤0.01% 2417
2025
Q1 		– Sell
-13,463
Closed -$114K – 3355
2024
Q4 		$114K Sell
13,463
-13,487
-50% -$140K ﹤0.01% 2951
2024
Q3 		$312K Sell
26,950
-1,247
-4% -$15.7K ﹤0.01% 2654
2024
Q2 		$332K Sell
28,197
-163,502
-85% -$1.91M ﹤0.01% 2549
2024
Q1 		$2.27M Buy
191,699
+25,940
+16% +$346K 0.01% 1395
2023
Q4 		$2.03M Buy
165,759
+61,965
+60% +$564K ﹤0.01% 1530
2023
Q3 		$1,000K Buy
103,794
+4,632
+5% +$47.3K ﹤0.01% 1930
2023
Q2 		$892K Buy
99,162
+44,797
+82% +$413K ﹤0.01% 2002
2023
Q1 		$427K Buy
54,365
+36,949
+212% +$276K ﹤0.01% 2278
2022
Q4 		$118K Buy
+17,416
New +$93.3K ﹤0.01% 2487
2022
Q3 		– Sell
-37,453
Closed -$369K – 2642
2022
Q2 		$369K Buy
+37,453
New +$413K ﹤0.01% 1938
2022
Q1 		– Sell
-97,592
Closed -$1.29M – 3505
2021
Q4 		$1.29M Sell
97,592
-25,051
-20% -$399K ﹤0.01% 2330
2021
Q3 		$2.14M Buy
122,643
+65,765
+116% +$1.33M ﹤0.01% 1924
2021
Q2 		$1.36M Sell
56,878
-23,795
-29% -$623K ﹤0.01% 2207
2021
Q1 		$2.07M Buy
80,673
+52,277
+184% +$1.37M 0.01% 1685
2020
Q4 		$539K Buy
+28,396
New +$487K ﹤0.01% 2462
2020
Q3 		– Sell
-27,262
Closed -$330K – 3318
2020
Q2 		$330K Buy
+27,262
New +$290K ﹤0.01% 2310
2019
Q3 		– Sell
-13,696
Closed -$303K – 3635
2019
Q2 		$303K Buy
+13,696
New +$321K ﹤0.01% 2855
2018
Q4 		– Sell
-12,740
Closed -$282K – 3268
2018
Q3 		$282K Buy
+12,740
New +$172K ﹤0.01% 2806

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments's KALV Position: Q1 2026 in Review

Two Sigma Investments opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 153,459 shares worth $3.09M. The stake represents ﹤0.01% of the portfolio and ranks #2417 among its holdings. This is a return to the name: Two Sigma Investments previously reported a position in KALV as recently as Q4 2024.

Two Sigma Investments first reported a position in KALV in Q3 2018 and has held it in 19 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Two Sigma Investments held 153,459 shares of KalVista Pharmaceuticals worth $3.09M as of Q1 2026.
  • KalVista Pharmaceuticals was a new Two Sigma Investments position in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2417 holding.
  • Two Sigma Investments first reported a position in KalVista Pharmaceuticals in Q3 2018 and has held it in 19 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.